REPAIR Impact Fund

The REPAIR Impact Fund operates as a dedicated investment vehicle, deploying capital into companies engaged in the development of novel therapeutic solutions. Its core mission involves bolstering the global pipeline of antimicrobial agents to combat the escalating threat of antimicrobial resistance. The fund’s strategy focuses on identifying and supporting ventures that are pioneering innovative approaches to address critical gaps in the world's therapeutic arsenal against resistant pathogens.

The initiative was commissioned by the Novo Nordisk Foundation, with Novo Holdings responsible for its execution and management. This structure was established to channel significant resources and expertise towards a pressing global health challenge, leveraging the foundation's philanthropic vision and Novo Holdings' investment acumen to foster advancements in the AMR landscape.

The fund's beneficiaries are pharmaceutical and biotechnology companies specializing in anti-infective research and development. These enterprises leverage the fund's investments to advance their programs, ultimately bringing new therapies to market. The overarching vision is to safeguard public health by continually expanding and improving humanity's capacity to effectively treat infectious diseases, ensuring a future where antibiotic efficacy is preserved.